Vogenx eyes $67M IPO for mizagliflozin; Ratio raises $70M for radiopharma trials; Impact Therapeutics sells senaparib rights for $486.5M; Apple Tree faces legal setback.
Ratio Therapeutics secures $70M Series C for radiopharmaceutical trials; Vogenx pursues $67M IPO. Dual exits signal VC confidence in radiopharmaceutical automation maturity; AI-driven therapeutics increasingly attract late-stage capital and public market interest.
July 31, 2026 10:59 AM EDT
News Briefing
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Ratio Therapeutics raises $70M for radiopharma trials: The Boston biotech said the Series C funding came from existing investors Duquesne Family …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Three biotechs with three news updates
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical…
VolitionRx Announces Pricing of $4.6 Million Public Offering
